In T1DM patients, anti-CD3 therapy has been shown to reverse hyperglycaemia and improve insulin production up to a year after injection; anti-C20 therapy has been shown to delay β cell degradation, though it does not halt the disease; and anti-CD2 therapy has been shown to improve β cell function, even a year after therapy ended [245–247]. This evidence concerns the gene INS and type 1 diabetes mellitus.